EP1484314A1 - Process for production of optically active beta-phenylalanine derivatives - Google Patents

Process for production of optically active beta-phenylalanine derivatives Download PDF

Info

Publication number
EP1484314A1
EP1484314A1 EP03703284A EP03703284A EP1484314A1 EP 1484314 A1 EP1484314 A1 EP 1484314A1 EP 03703284 A EP03703284 A EP 03703284A EP 03703284 A EP03703284 A EP 03703284A EP 1484314 A1 EP1484314 A1 EP 1484314A1
Authority
EP
European Patent Office
Prior art keywords
group
optically active
formula
hydrogen atom
alkyl group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03703284A
Other languages
German (de)
French (fr)
Other versions
EP1484314A4 (en
Inventor
Hiroyuki Nohira
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ajinomoto Co Inc
Original Assignee
Ajinomoto Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Co Inc filed Critical Ajinomoto Co Inc
Publication of EP1484314A1 publication Critical patent/EP1484314A1/en
Publication of EP1484314A4 publication Critical patent/EP1484314A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/22—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
    • C07C215/28—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • C07C215/30—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings containing hydroxy groups and carbon atoms of six-membered aromatic rings bound to the same carbon atom of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/27—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/16—Preparation of optical isomers
    • C07C231/20—Preparation of optical isomers by separation of optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Definitions

  • the present invention relates to methods for producing optically active N-acyl- ⁇ -phenylalanine derivatives.
  • the present invention also relates tomethods for producing optically active ⁇ -phenylalanine derivatives.
  • the present invention further relates to diastereomer salts of N-acyl- ⁇ -phenylalanine derivatives.
  • a ⁇ -phenylalanine derivative means ⁇ -phenylalanine having a substituent on its phenyl group (a ⁇ -phenylalanine derivative in the narrow sense), but, when there is no risk of misunderstanding in terms of the context, not only the ⁇ -phenylalanine derivative in the narrow sense but also ⁇ -phenylalanine per se may be referred to as a ⁇ -phenylalanine derivative (in the broad sense).
  • Optically active ⁇ -phenylalanine derivatives are known to be material for receptor antagonists and enzyme inhibitors and are compounds which are useful as intermediates for pharmaceuticals such as antithrombotic agent, etc.
  • Known methods for the production of optically active ⁇ -phenylalanine derivatives include a method in which a racemic ⁇ -phenylalanine derivative is enzymatically resolved (see, for example, J. Org. Chem. , vol. 63, p.2351 (1998), as a method using penicillin acylase), a method in which the manufacture involves asymmetric synthesis (see, for example, J. Am. Chem. Soc. , vol.
  • an optically active N-acyl- ⁇ -phenylalanine derivative having a high optical purity may be obtained by converting an N-acyl- ⁇ -phenylalanine derivative, in which the amino group of the ⁇ -phenylalanine derivative is acylated, into diastereomers with a specific optically active compound (optically resolving agent),first selectively separating one of the diastereomers, then separating the other diastereomer, subjecting each of the separated salts to a double decomposition treatment, and further that an optically active ⁇ -phenylalanine derivative having a high optical purity may be obtained by deacylating one or both of the obtained optically active N-acyl- ⁇ -phenylalanine derivatives.
  • the present invention has been achieved.
  • the present invention includes the following.
  • optical resolution An operation by which a racemic substance is separated into each enantiomer, i.e. optical isomer, is called an optical resolution.
  • an optical resolution there is a direct method where a racemic substance is directly resolved into optical isomers and a method where a racemic substance is made to react with an optically active reagent (optical resolving agent) to give diastereomers, resolution into each diastereomer is conducted utilizing the difference in physical properties (such as solubility and the like) betweenthediastereomers, and the opticallyactive reagent is removed to give an optically active substance.
  • Representative means in the direct method are a preferential crystallization where crystals of an optical active substance (crystal seeds) are added to a saturated solution of a racemic substance to promote the crystallization whereupon an optical active substance is prepared (preferential crystallization method), and a column chromatography where an optically active stationary phase is used.
  • a typical method for the preparation of a diastereomer is that a diastereomer salt with an optically active base such as alkaloid, e.g., quinine and brucine, is prepared, recrystallization is conducted to separate it as a pure desired diastereomer salt and the resulting salt is decomposed with an acid or an alkali to give an optically active substance.”
  • an optically active base such as alkaloid, e.g., quinine and brucine
  • the method for producing an optically-active N-acyl- ⁇ -phenylalanine derivative according to the present invention utilizes an optically resolving agent (which may also be abbreviated as a diastereomer method) among the optically resolving methods as illustrated hereinabove. It should be noted that an important point in the development of the diastereomer method is that other operation conditions per se may be in accordance with the conventional methods in an appropriate manner.
  • R 1 is a hydrogen atom, a halogen atom, a nitro group, an alkyl group or an alkoxy group.
  • the halogen atom are a chlorine atom, a bromine atom, a fluorine atom, an iodine atom, etc.
  • the alkyl group are C 1-6 alkyl groups such as a methyl group, an ethyl group, a propyl group, a butyl group, and the like.
  • alkoxy group examples include C 1-6 alkoxy groups such as a methoxy group and an ethoxy group. These alkyl groups and the alkoxy groups as such may have one or more substituents such as a halogen atom or the like.
  • the ⁇ -phenylalanine derivative which is most preferably used as a starting material in the present production method according to the present invention is ⁇ -phenylalanine (or 3-amino-3-phenylpropanoic acid) where R 1 is a hydrogen atom.
  • R 1 in the N-acyl- ⁇ -phenylalanine derivatives represented by the above formula (1) (and an optically active substance thereof represented by the above formula (4)) in the present invention is the same as that mentioned already.
  • R 2 is a hydrogen atom, an alkyl group, an aryl group or an aralkyl group.
  • Examples of the alkyl group in R 2 are C 1-6 alkyl groups such as a methyl group, an ethyl group, a propyl group and the like; examples of the aryl group therein are C 6-10 aryl groups such as a phenyl group, a naphthyl group and the like; and examples of the aralkyl group therein are C 7-11 aralkyl groups such as a benzyl group and the like. These groups may have one or more substituents such as a halogen atom.
  • N-acyl- ⁇ -phenylalanine derivatives which are preferably used as the starting material in the production method of the present invention are N-acetyl- ⁇ -phenylalanine (or 3-acetylamino-3-phenylpropanoic acid) where R 1 is a hydrogen atom and R 2 is a methyl group, and N-formyl- ⁇ -phenylalanine (or 3-formylamino-3-phenylpropanoic acid) where R 1 and R 2 are both hydrogen atoms. It is particularly preferable to use N-acetyl- ⁇ -phenylalanine.
  • R 3 and R 4 are each independently a hydrogen atom, a halogen atom, a nitro group, an alkyl group or an alkoxy group.
  • the halogen atom are a chlorine atom, a bromine atom, a fluorine atom, an iodine atom, etc.
  • the alkyl group are C 1-6 alkyl groups such as a methyl group, an ethyl group, a propyl group, a butyl group, and the like.
  • Examples of the alkoxy group are C 1-6 alkoxy groups such as a methoxy group and an ethoxy group. These alkyl groups and alkoxy groups may have one or more substituents such as a halogen atom or the like.
  • optically active compounds represented by the above formula (2) or (3) which are particularly preferred for use in the formation of the diastereomer salt in the present invention are 2-amino-1,2-diphenylethanol and 2- (4-methylphenyl)-1-phenylethylamine where both R 3 and R 4 are hydrogen atoms.
  • 2-amino-1,2-diphenylethanol represented by the above formula (2) or (3)
  • 2- (4-methylphenyl)-1-phenylethylamine where both R 3 and R 4 are hydrogen atoms.
  • 2-(4-methylphenyl)-1-phenylethylamine and 2-amino-1,2-diphenylethanol are particularly preferably used, respectively.
  • optically active compound represented by the above formula (2) or (3) may be appropriately selected depending upon the desired configuration of the optically active N-acyl- ⁇ -phenylalanine derivative or optically active ⁇ -phenylalanine derivative.
  • (+)-3-acetylamino-3-phenylpropanoic acid may be prepared using (1R,2S)-(-)-2-amino-1,2-diphenylethanol while (-) -3-acetylamino-3-phenylpropanoic acid may be prepared using (1S,2R)-(+)-2-amino-1,2-diphenylethanol.
  • (+)-3-formylamino-3-phenylpropanoic acid may be prepared using (S)-(+)-2-(4-methylphenyl)-1-phenylethylamine while (-)-3-formylamino-3-phenylpropanoic acid may be prepared using (R)-(-)-2-(4-methylphenyl)-1-phenylethylamine.
  • R 1 , R 3 and R 4 which are substituents on the phenyl group may be present in plural for each phenyl group. In that case, the substituents may be the same or different.
  • N-acyl- ⁇ -phenylalanine derivative which is represented by the above formula (1) and used as a starting material in the production method of the present invention and the optically active compound (optically resolving agent) which is represented by the above formula (2) or (3) and used for the formation of the diastereomer salt may be used in a form of a salt so long as the advantage of the present invention is still achieved.
  • optically active N-acyl- ⁇ -phenylalanine derivative represented by the above formula (4) and the optically active ⁇ -phenylalanine derivative represented by the above formula (6) which are the desired substances may be separated and prepared in such a manner that the diastereomer salt is subjected to a double decomposition treatment and then the desired substance is converted into the form of an appropriate another salt from the decomposed solution if necessary.
  • such embodiments are also within the scope of the present invention.
  • the product may be prepared by the reaction of ⁇ -phenylalanine derivative using a carboxylic acid represented by the following formula (9) : R 2 -COOH as an acylating agent.
  • R 2 has the same meaning as defined already.
  • the formation of a diastereomer salt by the reaction of the N-acyl- ⁇ -phenylalanine derivative represented by the above formula (1) with the optically active compound (optically resolving agent) represented by the above formula (2) or (3), may be carried out by dissolving them in an appropriate solvent. It is not always necessary that the N-acyl- ⁇ -phenylalanine derivative is a racemic substance, but a substance in which the amount of one of the optically active substances is more than that of the other optically active substance (antipode) may also be subj ected to the method of the present invention for preparing one optically active compound.
  • the amount of the optically active compound (optically resolving agent) represented by the above formula (2) or (3) is usually within a range of 0.2 to 3 mol, preferably, 0.5 to 1. 5 to 1 mol of the N-acyl- ⁇ -phenylalanine derivative represented by the above formula (1).
  • the solvent used therefor so far as it is able to dissolve the N-acyl- ⁇ -phenylalanine derivative represented by the above formula (1) and the optically active compound (optically resolving agent) represented by the above formula (2) or (3).
  • preferred solvents are methanol, ethanol, isopropanol, acetone, methyl ethyl ketone, ethyl acetate and the like, and the particularly preferred one is methanol.
  • the amount of the solvent used it is usually used within a range of 1- to 50-fold by weight based on the weight of the N-acyl- ⁇ -phenylalanine represented by the above formula (1).
  • the thus-formed two kinds of diastereomer salts are subjected to an optical resolution so that one of the diastereomer salts is selectively separated.
  • the optical resolution may be carried out by means of crystallization in an appropriate solvent.
  • the preferred solvent for the crystallization are methanol, ethanol, isopropanol, acetone, methyl ethyl ketone, ethyl acetate and the like, and the particularly preferred one is ethanol.
  • the amount of the solvent used it is usually used within a range of 1- to 50-fold by weight based on the weight of the N-acyl- ⁇ -phenylalanine represent by the above formula (1).
  • the same solvent that is used for the formation of the salt may be used for the crystallization, whereby salt formation and crystallization may carried out continuously. It is further possible that, after formation of the salt, the solvent is evaporated, and crystallization is conducted using another solvent. Incidentally, crystals of the resulting diastereomer salt may also be further purified by dissolving them in an appropriate solvent and subjecting to a crystallization once again.
  • the resulting diastereomer salt crystals are subjected to a double decomposition treatment by known methods such as a double decomposition treatment with an acid or a base or a decomposition treatment with ion-exchange resin (this is also a kind of the double decomposition treatment), whereupon the optically active N-acyl- ⁇ -phenylalanine derivative represented by the above formula (4) is prepared.
  • the diastereomer salt is dissolved in a basic aqueous solution, the basic aqueous layer is extracted with an organic solvent (whereby the optical resolving agent is transferred to the organic solvent layer) , and an acid is added to the aqueous layer to make the aqueous layer acidic.
  • the resulting acidic aqueous layer is extracted with an organic solvent, and then the organic solvent is evaporated in vacuo from the extract to give the desired optically active N-acyl- ⁇ -phenylalanine derivative.
  • Examples of the base used here are sodium hydroxide, potassium hydroxide, magnesium hydroxide, calcium hydroxide, sodium carbonate, potassium carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate, and the like, and the particularly preferably used ones are sodium hydroxide and potassium hydroxide.
  • the acid hydrochloric acid, sulfuric acid, etc. are preferably used.
  • the organic solvent used for the extraction are diethyl ether, tetrahydrofuran, ethyl acetate, n-hexane, n-heptane, cyclohexane, toluene, xylene, dichloromethane, dichloroethane, and the like.
  • the amount of the base or the acid used is usually within a range of 1 to 200 mol to 1 mol of the diastereomer salt being subjected to the double decomposition, while the amount of the organic solvent used is usually within a range of 1- to 100-fold in terms of weight ratio to the diastereomer salt being subjected to the same treatment.
  • optically active N-acyl- ⁇ -phenylalanine derivative which is prepared as such may be further purified, if necessary, by recrystallization from an appropriate solvent suchasethanol.
  • optically active compound represented by the above formula (2) or (3) is recovered for recycling from the mother liquor, etc. after the double decomposition treatment.
  • the other diastereomer which is an antipode, is contained in the mother liquor (filtrate) obtained in a step, in which the diastereomers are formed and one of the diastereomer salts is separated as crystals, and, therefore, it is also possible that the solvent may be evaporated therefrom in vacuo, and the resulting residue is subjected to the same double decomposition treatment as above, to obtain the other enantiomer of the above-prepared optically N-acyl- ⁇ -phenylalanine derivative is prepared. In order to enhance its optical purity if necessary, it is preferred that the resulting enantiomer is purified by recrystallization using an appropriate solvent such as ethanol.
  • optically active N-acyl- ⁇ -phenylalanine derivative represented by the above formula (4) is subjected to a deacylation reaction known to persons skilled in the art, such as a deacylation using an acid, an optically active ⁇ -phenylalanine derivative represented by the above formula (6) is prepared.
  • the salt prepared in Example 2 was subjected to a double decomposition with a 1M aqueous solution of sodium hydroxide and a basic organic substance was extracted from the double-decomposed solution with ether.
  • 1M of hydrochloric acid was added to achieve the Congo Red acidic property, the organic substance was extracted with ethyl acetate, and the extract was dried by addition of anhydrous sodium sulfate thereto.
  • Example 2 The filtrate obtained in Example 2 was combined and concentrated in vacuo to give 834 mg of a residue containing (-)-3-acetylamino-3-phenylpropanoic acid and (1R,2S)-(-)-erythro-2-amino-1,2-diphenylethanol diastereomer salt. That was subjected to the same double decomposition treatment as in Example 3 to give 326 mg of crude (-)-3-acetylamino-3-phenylpropanoic acid (optical purity: 59.5%).
  • (+)-3-acetylamino-3-phenylpropanoic acid (207 mg, 1.00 mmol) prepared by the same manner as in Example 3 and 2.0 ml of 2M hydrochloric acid were added to a 30-mol two-necked flask equipped with a stirrer and heated to reflux for 3 hours. After 3 hours, 1 drop of concentrated hydrochloric acid was added to the reaction solution using a Pasteur pipette, and the mixture was heated to reflux for 2 hours more.
  • Formic acid (1.0 ml, 26.6 mmol) was added dropwise to 2.0 ml (21.4 mmol) of acetic anhydride in an ice bath. After that, the ice bath was removed, and the solution was stirred at 50°C for 15 minutes. After allowing to stand for 15 minutes, the resulting solution of the formic acid and the acetic anhydride was cooled again with an ice bath and was added dropwise to a solution of 586 mg (3.55 mmol) of ( ⁇ )-3-amino-3-phenylpropanoic acid in 0.5 ml of formic acid previously cooled at not higher than 10°C. The mixture was stirred for 40 minutes as it was, and, when the solution became room temperature, it was stirred for 80 minutes more.
  • Example 7 The salt obtained in Example 7 was subjected to a double decomposition using a 1M aqueous solution of sodium hydroxide, and the basic organic substance from the double decomposed solution with ether.
  • the aqueous layer after extracting with ether was made acidic to Congo Red, the organic substance was extracted with ethyl acetate, and the extract was dried by addition of anhydrous sodium sulfate thereto.
  • an optically active N-acyl- ⁇ -phenylalanine derivative and also an optically active ⁇ -phenylalanine derivative may be prepared in an efficient manner and an industrially excellent method for the production thereof is provided.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The present application discloses a method for the production of an optically active β-phenylalanine derivative in which an N-acyl-β-phenylalanine derivative is made to react with a specific optically resolving agent to conduct an optical resolution by formation of diastereomer salts, the optically resolving agent is removed from each diastereomer to give an optically active N-acyl-β-phenylalanine derivative and then a deacylation is further carried out, whereupon an optically active β-phenylalanine derivative is prepared. According to that method, an optically active N-acyl-β-phenylalanine derivative and an optically active β-phenylalanine derivative may be produced in an industrially advantageous manner.

Description

(Technical Field)
The present invention relates to methods for producing optically active N-acyl-β-phenylalanine derivatives. The present invention also relates tomethods for producing optically active β-phenylalanine derivatives. The present invention further relates to diastereomer salts of N-acyl-β-phenylalanine derivatives.
In the context of the present specification, a β-phenylalanine derivative means β-phenylalanine having a substituent on its phenyl group (a β-phenylalanine derivative in the narrow sense), but, when there is no risk of misunderstanding in terms of the context, not only the β-phenylalanine derivative in the narrow sense but also β-phenylalanine per se may be referred to as a β-phenylalanine derivative (in the broad sense).
(Background Art)
Optically active β-phenylalanine derivatives are known to be material for receptor antagonists and enzyme inhibitors and are compounds which are useful as intermediates for pharmaceuticals such as antithrombotic agent, etc. Known methods for the production of optically active β-phenylalanine derivatives include a method in which a racemic β-phenylalanine derivative is enzymatically resolved (see, for example, J. Org. Chem., vol. 63, p.2351 (1998), as a method using penicillin acylase), a method in which the manufacture involves asymmetric synthesis (see, for example, J. Am. Chem. Soc. , vol. 116, p.10520 (1994),as a method using an asymmetric aldol reaction), etc. However, it is difficult to obtain an optically active β-phenylalanine derivative having a high optical purity in an efficient manner. On the other hand, racemic β-phenylalanine derivatives may be relatively easily produced by synthesis means (see, for example, J. Am. Chem. Soc. , vol. 51, p.841 (1929)). Thus, there has been a demand for the development of a process for the optical resolution of a racemic substance for the production of optically active β-phenylalanine derivatives.
(Disclosure of the Invention) [Problems to be Solved by the Invention]
Under the above-mentioned background art, it is an object of the present invention to provide industrially advantageous methods for making optically active N-acyl-β-phenylalanine derivatives, and subsequently optically active β-phenylalanine derivatives, both being useful as intermediates for pharmaceuticals, etc.
[Means for Solving the Problems]
In order to achieve the above-mentioned obj ect, the present inventor has carried out intensive studies, and, as a result, found that an optically active N-acyl-β-phenylalanine derivative having a high optical purity may be obtained by converting an N-acyl-β-phenylalanine derivative, in which the amino group of the β-phenylalanine derivative is acylated, into diastereomers with a specific optically active compound (optically resolving agent),first selectively separating one of the diastereomers, then separating the other diastereomer, subjecting each of the separated salts to a double decomposition treatment, and further that an optically active β-phenylalanine derivative having a high optical purity may be obtained by deacylating one or both of the obtained optically active N-acyl-β-phenylalanine derivatives. On the basis of these findings, the present invention has been achieved.
Thus, the present invention includes the following.
  • [1] A method for producing an optically active N-acyl-β-phenylalanine derivative represented by the following formula (4):
    Figure 00040001
    [in the formula, R1, R2 and * have the same meanings as defined below],
    which method comprises reacting an N-acyl-β-phenylalanine derivative represented by the following formula (1):
    Figure 00040002
    [in the formula, R1 is a hydrogen atom, a halogen atom, a nitro group, an alkyl group or an alkoxy group; and R2 is a hydrogen atom, an alkyl group, an aryl group or an aralkyl group] with either an optically active compound represented by the following formula (2):
    Figure 00040003
    [in the formula, R3 and R4 each independently is a hydrogen atom, a halogen atom, a nitro group, an alkyl group or an alkoxy group; and * means that a carbon atom having it is an asymmetric carbon atom], or
    an optically active compound represented by the following formula (3) :
    Figure 00050001
    [in the formula, R3, R4 and * have the same meanings as defined above], to obtain a diastereomer salt,
    subjecting the resulting diastereomer salt to an optical resolution, to obtain an optically active diastereomer salt, and subjecting the resulting optically active diastereomer salt to a double decomposition treatment.
  • [2] A method for producing an optically active N-acyl-β-phenylalanine derivative represented by the following formula (4):
    Figure 00050002
    [in the formula, R1, R2 and * have the same meaning as defined below],
    which method comprises acylating the amino group of a β-phenylalanine derivative represented by the following formula (5) :
    Figure 00060001
    [in the formula, R1 is a hydrogen atom, a halogen atom, a nitro group, an alkyl group or an alkoxy group], to obtain an N-acyl-β-phenylalanine derivative represented by the following formula (1):
    Figure 00060002
    [in the formula, R1 is a hydrogen atom, a halogen atom, a nitro group, an alkyl group or an alkoxy group; and R2 is a hydrogen atom, an alkyl group, an aryl group or an aralkyl group], reacting the resulting derivative with either an optically active compound represented by the following formula (2):
    Figure 00060003
    [in the formula, R3 and R4 each independently is a hydrogen atom, a halogen atom, a nitro group, an alkyl group or an alkoxy group; and * means that a carbon atom having it is an asymmetric carbon atom] or
    an optically active compound represented by the following formula (3):
    Figure 00070001
    [in the formula, R3, R4 and * have the same meanings as defined above], to obtain a diastereomer salt,
    subjecting the resulting diastereomer salt to an optical resolution, to obtain an optically active diastereomer salt, and subjecting the resulting optically active diastereomer salt to a double decomposition treatment.
  • [3] The method according to [1] or [2], wherein the opt ical resolution is carried out by crystallization of the diastereomer salt.
  • [4] A method for producing an optically active β-phenylalanine derivative represented by the following formula (6) :
    Figure 00070002
    [in the formula, R1 is a hydrogen atom, a halogen atom, a nitro group, an alkyl group or an alkoxy group; R2 is a hydrogen atom, an alkyl group, an aryl group or an aralkyl group; and * means that a carbon atom having it is an asymmetric carbon atom], which method comprises preparing an optically active N-acyl-β-phenylalanine derivative represented by the above-mentioned formula (4) according to any of the methods [1] to [3], and
    subjecting the resulting derivative to a deacylation reaction.
  • [5] A diastereomer salt which is represented by the following formula (7):
    Figure 00080001
    [in the formula, R1 is a hydrogen atom, a halogen atom, a nitro group, an alkyl group or an alkoxy group; R2 is a hydrogen atom, an alkyl group, an aryl group or an aralkyl group; R3 and R4 are each independently a hydrogen atom, a halogen atom, a nitro group, an alkyl group or an alkoxy group; and * means that a carbon atom having it is an asymmetric carbon atom].
  • [6] A diastereomer salt which is represented by the following formula (8):
    Figure 00090001
    [in the formula, R1 is a hydrogen atom, a halogen atom, a nitro group, an alkyl group or an alkoxy group; R2 is a hydrogen atom, an alkyl group, an aryl group or an aralkyl group; R3 and R4 are each independently a hydrogen atom, a halogen atom, a nitro group, an alkyl group or an alkoxy group; and * means that a carbon atom having it is an asymmetric carbon atom].
    • (Embodiments of the Invention)
    The present invention will now be illustrated in more detail below.
    Firstly, the term optical resolution is defined as follows for example. "Optical resolution - An operation by which a racemic substance is separated into each enantiomer, i.e. optical isomer, is called an optical resolution. In an optical resolution, there is a direct method where a racemic substance is directly resolved into optical isomers and a method where a racemic substance is made to react with an optically active reagent (optical resolving agent) to give diastereomers, resolution into each diastereomer is conducted utilizing the difference in physical properties (such as solubility and the like) betweenthediastereomers, and the opticallyactive reagent is removed to give an optically active substance. Representative means in the direct method are a preferential crystallization where crystals of an optical active substance (crystal seeds) are added to a saturated solution of a racemic substance to promote the crystallization whereupon an optical active substance is prepared (preferential crystallization method), and a column chromatography where an optically active stationary phase is used. When a racemic substance is an acid for example, a typical method for the preparation of a diastereomer is that a diastereomer salt with an optically active base such as alkaloid, e.g., quinine and brucine, is prepared, recrystallization is conducted to separate it as a pure desired diastereomer salt and the resulting salt is decomposed with an acid or an alkali to give an optically active substance." (" Kagaku Jiten " (Encyclopedic Dictionary of Chemistry), page 458, published by Tokyo Kagaku Dojin in 1994).
    Among the optically resolving methods as illustrated above, the method for producing an optically-active N-acyl-β-phenylalanine derivative according to the present invention utilizes an optically resolving agent (which may also be abbreviated as a diastereomer method) among the optically resolving methods as illustrated hereinabove. It should be noted that an important point in the development of the diastereomer method is that other operation conditions per se may be in accordance with the conventional methods in an appropriate manner.
    Now, in the β-phenylalanine derivative represented by the above formula (5) in the present invention (and optically active substances thereof represented by the above formula (6)), R1 is a hydrogen atom, a halogen atom, a nitro group, an alkyl group or an alkoxy group. Examples of the halogen atom are a chlorine atom, a bromine atom, a fluorine atom, an iodine atom, etc. Examples of the alkyl group are C1-6 alkyl groups such as a methyl group, an ethyl group, a propyl group, a butyl group, and the like. Examples of the alkoxy group are C1-6 alkoxy groups such as a methoxy group and an ethoxy group. These alkyl groups and the alkoxy groups as such may have one or more substituents such as a halogen atom or the like. The β-phenylalanine derivative which is most preferably used as a starting material in the present production method according to the present invention is β-phenylalanine (or 3-amino-3-phenylpropanoic acid) where R1 is a hydrogen atom.
    R1 in the N-acyl-β-phenylalanine derivatives represented by the above formula (1) (and an optically active substance thereof represented by the above formula (4)) in the present invention is the same as that mentioned already. R2 is a hydrogen atom, an alkyl group, an aryl group or an aralkyl group. Examples of the alkyl group in R2 are C1-6 alkyl groups such as a methyl group, an ethyl group, a propyl group and the like; examples of the aryl group therein are C6-10 aryl groups such as a phenyl group, a naphthyl group and the like; and examples of the aralkyl group therein are C7-11 aralkyl groups such as a benzyl group and the like. These groups may have one or more substituents such as a halogen atom. The N-acyl-β-phenylalanine derivatives which are preferably used as the starting material in the production method of the present invention are N-acetyl-β-phenylalanine (or 3-acetylamino-3-phenylpropanoic acid) where R1 is a hydrogen atom and R2 is a methyl group, and N-formyl-β-phenylalanine (or 3-formylamino-3-phenylpropanoic acid) where R1 and R2 are both hydrogen atoms. It is particularly preferable to use N-acetyl-β-phenylalanine.
    In the optically active compound (optically resolving agent) represented by the above formula (2) or (3) in the present invention, R3 and R4 are each independently a hydrogen atom, a halogen atom, a nitro group, an alkyl group or an alkoxy group. Examples of the halogen atom are a chlorine atom, a bromine atom, a fluorine atom, an iodine atom, etc. Examples of the alkyl group are C1-6 alkyl groups such as a methyl group, an ethyl group, a propyl group, a butyl group, and the like. Examples of the alkoxy group are C1-6 alkoxy groups such as a methoxy group and an ethoxy group. These alkyl groups and alkoxy groups may have one or more substituents such as a halogen atom or the like.
    The optically active compounds (optically resolving agent) represented by the above formula (2) or (3) which are particularly preferred for use in the formation of the diastereomer salt in the present invention are 2-amino-1,2-diphenylethanol and 2- (4-methylphenyl)-1-phenylethylamine where both R3 and R4 are hydrogen atoms. For N-formyl-β-phenylalanine and N-acetyl-β-phenylalanine, 2-(4-methylphenyl)-1-phenylethylamine and 2-amino-1,2-diphenylethanol are particularly preferably used, respectively.
    The configuration of the optically active compound represented by the above formula (2) or (3) (optically resolving agent) may be appropriately selected depending upon the desired configuration of the optically active N-acyl-β-phenylalanine derivative or optically active β-phenylalanine derivative. Thus, for example, (+)-3-acetylamino-3-phenylpropanoic acid may be prepared using (1R,2S)-(-)-2-amino-1,2-diphenylethanol while (-) -3-acetylamino-3-phenylpropanoic acid may be prepared using (1S,2R)-(+)-2-amino-1,2-diphenylethanol. Further, for example, (+)-3-formylamino-3-phenylpropanoic acid may be prepared using (S)-(+)-2-(4-methylphenyl)-1-phenylethylamine while (-)-3-formylamino-3-phenylpropanoic acid may be prepared using (R)-(-)-2-(4-methylphenyl)-1-phenylethylamine.
    In the compound according to the present invention, R1, R3 and R4 which are substituents on the phenyl group may be present in plural for each phenyl group. In that case, the substituents may be the same or different.
    The N-acyl-β-phenylalanine derivative which is represented by the above formula (1) and used as a starting material in the production method of the present invention and the optically active compound (optically resolving agent) which is represented by the above formula (2) or (3) and used for the formation of the diastereomer salt may be used in a form of a salt so long as the advantage of the present invention is still achieved. The optically active N-acyl-β-phenylalanine derivative represented by the above formula (4) and the optically active β-phenylalanine derivative represented by the above formula (6) which are the desired substances may be separated and prepared in such a manner that the diastereomer salt is subjected to a double decomposition treatment and then the desired substance is converted into the form of an appropriate another salt from the decomposed solution if necessary. Thus, such embodiments are also within the scope of the present invention.
    There is no particular limitation of the method for acylating the β-phenylalanine derivative represented by the above formula (5) ; any method which is known to persons skilled in the art may be appropriately used. For example, the product may be prepared by the reaction of β-phenylalanine derivative using a carboxylic acid represented by the following formula (9) : R2-COOH as an acylating agent. In the formula, R2 has the same meaning as defined already.
    The formation of a diastereomer salt by the reaction of the N-acyl-β-phenylalanine derivative represented by the above formula (1) with the optically active compound (optically resolving agent) represented by the above formula (2) or (3), may be carried out by dissolving them in an appropriate solvent. It is not always necessary that the N-acyl-β-phenylalanine derivative is a racemic substance, but a substance in which the amount of one of the optically active substances is more than that of the other optically active substance (antipode) may also be subj ected to the method of the present invention for preparing one optically active compound.
    The amount of the optically active compound (optically resolving agent) represented by the above formula (2) or (3) is usually within a range of 0.2 to 3 mol, preferably, 0.5 to 1. 5 to 1 mol of the N-acyl-β-phenylalanine derivative represented by the above formula (1).
    There is no particular limitation for the solvent used therefor so far as it is able to dissolve the N-acyl-β-phenylalanine derivative represented by the above formula (1) and the optically active compound (optically resolving agent) represented by the above formula (2) or (3). Examples of preferred solvents are methanol, ethanol, isopropanol, acetone, methyl ethyl ketone, ethyl acetate and the like, and the particularly preferred one is methanol. Although there is no particular limitation for the amount of the solvent used, it is usually used within a range of 1- to 50-fold by weight based on the weight of the N-acyl-β-phenylalanine represented by the above formula (1).
    After that, the thus-formed two kinds of diastereomer salts are subjected to an optical resolution so that one of the diastereomer salts is selectively separated. The optical resolution may be carried out by means of crystallization in an appropriate solvent. Examples of the preferred solvent for the crystallization are methanol, ethanol, isopropanol, acetone, methyl ethyl ketone, ethyl acetate and the like, and the particularly preferred one is ethanol. Although there is no particular limitation for the amount of the solvent used, it is usually used within a range of 1- to 50-fold by weight based on the weight of the N-acyl-β-phenylalanine represent by the above formula (1). It is also possible that the same solvent that is used for the formation of the salt may be used for the crystallization, whereby salt formation and crystallization may carried out continuously. It is further possible that, after formation of the salt, the solvent is evaporated, and crystallization is conducted using another solvent. Incidentally, crystals of the resulting diastereomer salt may also be further purified by dissolving them in an appropriate solvent and subjecting to a crystallization once again.
    The resulting diastereomer salt crystals are subjected to a double decomposition treatment by known methods such as a double decomposition treatment with an acid or a base or a decomposition treatment with ion-exchange resin (this is also a kind of the double decomposition treatment), whereupon the optically active N-acyl-β-phenylalanine derivative represented by the above formula (4) is prepared.
    In the case of a double decomposition with a base for example, the diastereomer salt is dissolved in a basic aqueous solution, the basic aqueous layer is extracted with an organic solvent (whereby the optical resolving agent is transferred to the organic solvent layer) , and an acid is added to the aqueous layer to make the aqueous layer acidic. The resulting acidic aqueous layer is extracted with an organic solvent, and then the organic solvent is evaporated in vacuo from the extract to give the desired optically active N-acyl-β-phenylalanine derivative. Examples of the base used here are sodium hydroxide, potassium hydroxide, magnesium hydroxide, calcium hydroxide, sodium carbonate, potassium carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate, and the like, and the particularly preferably used ones are sodium hydroxide and potassium hydroxide. With regard to the acid, hydrochloric acid, sulfuric acid, etc. are preferably used. Examples of the organic solvent used for the extraction are diethyl ether, tetrahydrofuran, ethyl acetate, n-hexane, n-heptane, cyclohexane, toluene, xylene, dichloromethane, dichloroethane, and the like. The amount of the base or the acid used is usually within a range of 1 to 200 mol to 1 mol of the diastereomer salt being subjected to the double decomposition, while the amount of the organic solvent used is usually within a range of 1- to 100-fold in terms of weight ratio to the diastereomer salt being subjected to the same treatment.
    The optically active N-acyl-β-phenylalanine derivative which is prepared as such may be further purified, if necessary, by recrystallization from an appropriate solvent suchasethanol.
    It is also possible that the optically active compound represented by the above formula (2) or (3) is recovered for recycling from the mother liquor, etc. after the double decomposition treatment.
    The other diastereomer, which is an antipode, is contained in the mother liquor (filtrate) obtained in a step, in which the diastereomers are formed and one of the diastereomer salts is separated as crystals, and, therefore, it is also possible that the solvent may be evaporated therefrom in vacuo, and the resulting residue is subjected to the same double decomposition treatment as above, to obtain the other enantiomer of the above-prepared optically N-acyl-β-phenylalanine derivative is prepared. In order to enhance its optical purity if necessary, it is preferred that the resulting enantiomer is purified by recrystallization using an appropriate solvent such as ethanol.
    When the resulting optically active N-acyl-β-phenylalanine derivative represented by the above formula (4) is subjected to a deacylation reaction known to persons skilled in the art, such as a deacylation using an acid, an optically active β-phenylalanine derivative represented by the above formula (6) is prepared.
    (Best Mode for Carrying Out the Invention)
    The present invention will now be illustrated in more detail by way of the following Examples, but the present invention is not limited to those Examples. Measurement of the optical purity of the resulting substance was carried out by means of a high-performance liquid chromatography using an optically active column.
    <Example 1: N-Acetylation of β-phenylalanine>
    (±)-3-Amino-3-phenylpropanoic acid (2.378 g, 14.4 mmol), 2.0 ml of acetic acid and 236 mg (2.88 mmol) of anhydrous sodium acetate were charged in a 30-ml two-necked round-bottomed flask equipped with a stirrer and a calcium chloride tube and cooled down to not higher than 10°C using an ice bath. Acetic anhydride ( 4 ml, 42.8 mmol) cooled at not higher than 10°C was added dropwise into the solution, and the mixture was stirred for 40 minutes at that temperature and then stirred for 80 minutes at room temperature.
    After completion of the reaction, the reaction solution was washed with distilled water and extracted with ethyl acetate. After that, the extract was dried for one night over anhydrous sodium sulfate, and the solvent was evaporated in vacuo. The residue was recrystallized from 99% ethanol to give 2.40 g (11.6 mmol) of (±)-3-acetylamino-3-phenylpropanoic acid in a yield of 80.5% (melting point: 161 to 162°C).
    <Example 2: Optical resolution of N-acetyl-β-phenylalanine by a diastereomer method>
    Each of 622 mg (3.0 mmol) of (±)-3-acetylamino-3-phenylpropanoic acid and 640 mg (3.03 mmol) of (1R,2S)-(-)-erythro-2-amino-1,2-diphenylethanol (the chemical formula thereof is given at the end of this Example) were dissolved in an appropriate amount of ethanol to form diastereomer salts. The solvent was evaporated in vacuo from the resulting solution and the residue was placed in a 30-ml Erlenmeyer flask equipped with an Allihn condenser and heated to reflux after addition of 7.0 ml of 99% ethanol to completely dissolve.
    The solution was allowed to stand for one night, and the separated crystals were dried under reduced pressure in a desiccator for one night to give 621 mg (1.48 mmol) of crude crystals of (+)-3-acetylamino-3-phenylpropanoic acid and (1R,2S)-(-)-erythro-2-amino-1,2-diphenylethanol. The resulting crude crystals were recrystallized from 99% ethanol, and the crystals were filtered to give 435 mg (1.03 mmol) of the salt crystals in a yield of 68.7% (melting point: 163 to 164°C, [α]D = -30.3° (c = 1.0, methanol)).
    Figure 00210001
    (1R,2S)-(-)-erythro-2-amino-1,2-diphenylethanol
    <Example 3: Preparation of an optically active N-acetyl-β-phenylalanine by a double decomposition of the salt>
    The salt prepared in Example 2 was subjected to a double decomposition with a 1M aqueous solution of sodium hydroxide and a basic organic substance was extracted from the double-decomposed solution with ether. To the aqueous layer after extracting with ether, 1M of hydrochloric acid was added to achieve the Congo Red acidic property, the organic substance was extracted with ethyl acetate, and the extract was dried by addition of anhydrous sodium sulfate thereto. After that, the ethyl acetate was evaporated in vacuo to give 174 mg (0.840mmol) of (+) -3-acetylamino-3-phenylpropanoic acid in a yield of 56.0% (melting point: 190 to 191°C, [α]D = +84.9° (c = 0.6, methanol) , optical purity > 99.0% e.e.).
    <Example 4: Preparation of an optically active N-acetyl-β-phenylalanine which is the antipode>
    The filtrate obtained in Example 2 was combined and concentrated in vacuo to give 834 mg of a residue containing (-)-3-acetylamino-3-phenylpropanoic acid and (1R,2S)-(-)-erythro-2-amino-1,2-diphenylethanol diastereomer salt. That was subjected to the same double decomposition treatment as in Example 3 to give 326 mg of crude (-)-3-acetylamino-3-phenylpropanoic acid (optical purity: 59.5%). This was recrystallized from 99% ethanol to give 151 mg (0.729 mmol) of (-)-3-acetylamino-3-phenylpropanoic acid in a yield of 48.6% (melting point: 191 to 192°C, [α]D = -84.5° (c = 0.1, methanol), optical purity > 99.0% e.e.).
    <Example 5: Deacetylation of N-acetyl-β-phenylalanine>
    (+)-3-acetylamino-3-phenylpropanoic acid (207 mg, 1.00 mmol) prepared by the same manner as in Example 3 and 2.0 ml of 2M hydrochloric acid were added to a 30-mol two-necked flask equipped with a stirrer and heated to reflux for 3 hours. After 3 hours, 1 drop of concentrated hydrochloric acid was added to the reaction solution using a Pasteur pipette, and the mixture was heated to reflux for 2 hours more. After completion of the reaction, the reaction solution was evaporated to dryness in vacuo, and the resulting residue was washed with a mixed solvent of methanol/diisopropyl and recrystallized from a mixed solvent of 2-propanol/99% ethanol to give 79 mg (0.392 mmol) of (+)-3-amino-3-phenylpropanoic acid hydrochloride in a yield of 39.2% (melting point: 195 to 196°C, [α]D = -3.03° (c = 1.0, methanol)).
    <Example 6: N-Formylation of β-phenylalanine>
    Formic acid (1.0 ml, 26.6 mmol) was added dropwise to 2.0 ml (21.4 mmol) of acetic anhydride in an ice bath. After that, the ice bath was removed, and the solution was stirred at 50°C for 15 minutes. After allowing to stand for 15 minutes, the resulting solution of the formic acid and the acetic anhydride was cooled again with an ice bath and was added dropwise to a solution of 586 mg (3.55 mmol) of (±)-3-amino-3-phenylpropanoic acid in 0.5 ml of formic acid previously cooled at not higher than 10°C. The mixture was stirred for 40 minutes as it was, and, when the solution became room temperature, it was stirred for 80 minutes more. The residue prepared by concentrating the reaction solution in vacuo was recrystallized from water to give 624 mg (3.23 mmol) of (±)-3-formylamino-3-phenylpropanoic acid in a yield of 91.0% (melting point: 127 to 128°C).
    <Example 7: Optical resolution of N-formyl-β-phenylalanine by a diastereomer method>
    Each of 579 mg (3.0 mmol) of (±)-3-formylamino-3-phenylpropanoic acid and 634 mg (3.0 mmol) of (R)-(-)-2-(4-methylphenyl)-1-phenylethylamine (the chemical formula thereof is given at the end of this Example) were dissolved in an appropriate amount of methanol to form diastereomer salts. The solvent was evaporated in vacuo from the resulting solution, and the residue was placed in a 10-ml Erlenmeyer flask equipped with an Allihn condenser and heated to reflux after addition of 1.8 ml of 99% ethanol to completely dissolve.
    The solution was allowed to stand for one night, and the separated crystals were dried under reduced pressure in a desiccator for one night to give 617 mg (1.53 mmol) of crude crystals of (-)-3-formylamino-3-phenylpropanoic acid and (R)-(-)-2-(4-methylphenyl)-1-phenylethylamine. The resulting crude crystals were recrystallized from 99% ethanol three times, and the crystals were filtered to give 230 mg (0.57 mmol) of the salt crystals in a yield of 37.9% (melting point: 160 to 161°C, [α]D = -105° (c = 1.0, methanol)).
    Figure 00240001
       (R)-(-)-2-(4-methylphenyl)-1-phenylethylamine
    <Example 8: Preparation of an optically active N-formyl-β-phenylalanine by a double decomposition of the salt>
    The salt obtained in Example 7 was subjected to a double decomposition using a 1M aqueous solution of sodium hydroxide, and the basic organic substance from the double decomposed solution with ether. The aqueous layer after extracting with ether was made acidic to Congo Red, the organic substance was extracted with ethyl acetate, and the extract was dried by addition of anhydrous sodium sulfate thereto. After that, the ethyl acetate was evaporated in vacuo from the dried extract to give 92 mg (0.476 mmol) of (-)-3-formylamino-3-phenylpropanoic acid in a yield of 31.7% (melting point: 135 to 136°C, [α]D = -111° (c = 0.5, methanol), optical purity > 99.0% e.e.).
    (Industrial Applicability)
    In accordance with the method of the present invention, an optically active N-acyl-β-phenylalanine derivative and also an optically active β-phenylalanine derivative may be prepared in an efficient manner and an industrially excellent method for the production thereof is provided.

    Claims (6)

    1. A method for producing an optically active N-acyl-β-phenylalanine derivative represented by the following formula (4):
      Figure 00260001
      [in the formula, R1, R2 and * have the same meanings as defined below],
      which method comprises reacting an N-acyl-β-phenylalanine derivative represented by the following formula (1):
      Figure 00260002
      [in the formula, R1 is a hydrogen atom, a halogen atom, a nitro group, an alkyl group or an alkoxy group; and R2 is a hydrogen atom, an alkyl group, an aryl group or an aralkyl group] with either an optically active compound represented by the following formula (2):
      Figure 00270001
      [in the formula, R3 and R4 each independently is a hydrogen atom, a halogen atom, a nitro group, an alkyl group or an alkoxy group; and * means that a carbon atom having it is an asymmetric carbon atom], or
      an optically active compound represented by the following formula (3) :
      Figure 00270002
      [in the formula, R3, R4 and * have the same meanings as defined above], to obtain a diastereomer salt,
      subjecting the resulting diastereomer salt to an optical resolution, to obtain an optically active diastereomer salt, and
      subjecting the resulting optically active diastereomer salt to a double decomposition treatment.
    2. A method for producing an optically active N-acyl-β-phenylalanine derivative represented by the following formula (4):
      Figure 00280001
      [in the formula, R1, R2 and * have the same meaning as defined below],
      which method comprises acylating the amino group of a β-phenylalanine derivative represented by the following formula (5):
      Figure 00280002
      [in the formula, R1 is a hydrogen atom, a halogen atom, a nitro group, an alkyl group or an alkoxy group], to obtain an N-acyl-β-phenylalanine derivative represented by the following formula (1):
      Figure 00280003
      [in the formula, R1 is a hydrogen atom, a halogen atom, a nitro group, an alkyl group or an alkoxy group; and R2 is a hydrogen atom, an alkyl group, an aryl group or an aralkyl group], reacting the resulting derivative with either an optically active compound represented by the following formula (2):
      Figure 00290001
      [in the formula, R3 and R4 each independently is a hydrogen atom, a halogen atom, a nitro group, an alkyl group or an alkoxy group; and * means that a carbon atom having it is an asymmetric carbon atom] or
      an optically active compound represented by the following formula (3) :
      Figure 00290002
      [in the formula, R3, R4 and * have the same meanings as defined above], to obtain a diastereomer salt,
      subjecting the resulting diastereomer salt to an optical resolution, to obtain an optically active diastereomer salt, and
      subjecting the resulting optically active diastereomer salt to a double decomposition treatment.
    3. The method according to Claim 1 or 2, wherein the optical resolution is carried out by crystallization of the diastereomer salt.
    4. A method for producing an optically active β-phenylalanine derivative represented by the following formula (6):
      Figure 00300001
      [in the formula, R1 is a hydrogen atom, a halogen atom, a nitro group, an alkyl group or an alkoxy group; R2 is a hydrogen atom, an alkyl group, an aryl group or an aralkyl group; and * means that a carbon atom having it is an asymmetric carbon atom], which method comprises preparing an optically active N-acyl-β-phenylalanine derivative represented by the above-mentioned formula (4) according to any of the methods of Claims 1 to 3, and
      subjecting the resulting derivative to a deacylation reaction.
    5. A diastereomer salt which is represented by the following formula (7):
      Figure 00300002
      [in the formula, R1 is a hydrogen atom, a halogen atom, a nitro group, an alkyl group or an alkoxy group; R2 is a hydrogen atom, an alkyl group, an aryl group or an aralkyl group; R3 and R4 are each independently a hydrogen atom, a halogen atom, a nitro group, an alkyl group or an alkoxy group; and * means that a carbon atom having it is an asymmetric carbon atom].
    6. A diastereomer salt which is represented by the following formula (8):
      Figure 00310001
      [in the formula, R1 is a hydrogen atom, a halogen atom, a nitro group, an alkyl group or an alkoxy group; R2 is a hydrogen atom, an alkyl group, an aryl group or an aralkyl group; R3 and R4 are each independently a hydrogen atom, a halogen atom, a nitro group, an alkyl group or an alkoxy group; and * means that a carbon atom having it is an asymmetric carbon atom].
    EP03703284A 2002-02-15 2003-02-10 Process for production of optically active beta-phenylalanine derivatives Withdrawn EP1484314A4 (en)

    Applications Claiming Priority (3)

    Application Number Priority Date Filing Date Title
    JP2002038757A JP4126921B2 (en) 2002-02-15 2002-02-15 Process for producing optically active β-phenylalanine derivative
    JP2002038757 2002-02-15
    PCT/JP2003/001363 WO2003068727A1 (en) 2002-02-15 2003-02-10 PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE β-PHENYLALANINE DERIVATIVES

    Publications (2)

    Publication Number Publication Date
    EP1484314A1 true EP1484314A1 (en) 2004-12-08
    EP1484314A4 EP1484314A4 (en) 2005-04-13

    Family

    ID=27678199

    Family Applications (1)

    Application Number Title Priority Date Filing Date
    EP03703284A Withdrawn EP1484314A4 (en) 2002-02-15 2003-02-10 Process for production of optically active beta-phenylalanine derivatives

    Country Status (5)

    Country Link
    US (1) US7385080B2 (en)
    EP (1) EP1484314A4 (en)
    JP (1) JP4126921B2 (en)
    AU (1) AU2003207195A1 (en)
    WO (1) WO2003068727A1 (en)

    Families Citing this family (2)

    * Cited by examiner, † Cited by third party
    Publication number Priority date Publication date Assignee Title
    JP5122871B2 (en) * 2007-06-01 2013-01-16 大東化学株式会社 Process for producing optically active N-benzyloxycarbonylamino acid and diastereomeric salt
    CN101633625B (en) * 2008-07-23 2013-02-13 江苏恒瑞医药股份有限公司 Method for preparing R-beta-aminobenzene butyric acid derivative

    Family Cites Families (9)

    * Cited by examiner, † Cited by third party
    Publication number Priority date Publication date Assignee Title
    JPS5521737B2 (en) * 1972-12-23 1980-06-12
    US4151198A (en) * 1978-06-02 1979-04-24 American Cyanamid Company Resolution of N-acyl-DL (+)-phenylalanines
    EP0174358A1 (en) * 1984-03-01 1986-03-19 ALKALOIDA VEGYéSZETI GYáR Novel diastereomer salts of phenylalanine and n-acyl derivatives thereof and process for the separation of optically active phenylalanine and n-acyl derivatives thereof
    HU190534B (en) 1984-04-11 1986-09-29 Egal Vegyipari Koezoes Vallalat,Hu Improved process for preparing l-beta-phenyl-alanine and acid addition salts tereof
    JPS62114945A (en) * 1985-11-15 1987-05-26 Toray Ind Inc Method of optical resolution of n-substituted-dl-phenylalanine
    JPH0615510B2 (en) * 1985-11-22 1994-03-02 和彦 西郷 Process for producing optically active erythro-2-amino-1,2-diphenylethanol and intermediate for production
    CA2023954C (en) * 1989-10-17 1999-05-04 Hiroyuki Nohira Process for the optical resolution of 2-(3-benzoyl) phenylpropionic acid
    JP3888402B2 (en) * 1997-07-30 2007-03-07 味の素株式会社 Process for producing optically active N-carbobenzoxy-tert-leucine
    EP1013769A1 (en) 1998-12-22 2000-06-28 Dsm N.V. Process for the enzymatic preparation of amino acid derivatives with enhanced optical purity

    Also Published As

    Publication number Publication date
    AU2003207195A1 (en) 2003-09-04
    WO2003068727A1 (en) 2003-08-21
    US20050065366A1 (en) 2005-03-24
    JP4126921B2 (en) 2008-07-30
    JP2003238506A (en) 2003-08-27
    US7385080B2 (en) 2008-06-10
    EP1484314A4 (en) 2005-04-13

    Similar Documents

    Publication Publication Date Title
    JP2839344B2 (en) Method for producing cyclic amino acid and intermediate thereof
    SK283663B6 (en) Method of making (S)-(+)-3-(aminomethyl)-5-methylhexanoic acid
    US5191112A (en) Process for optical resolution of (±)-2-(3-benzoyl)-phenylpropionic acid
    CN101495427B (en) Resolution of alpha-(phenoxy)phenylacetic acid derivatives with naphthyl-alkylamines
    US7385080B2 (en) Method for producing optically active β-phenylalanine compounds
    JP2011098975A (en) Chiral pure n-(trans-4-isopropyl-cyclohexylcarbonyl)-d-phenylalanine and method for producing crystal structure transformation product thereof
    KR101465025B1 (en) The stereoselective manufacturing method of loxoprofen(2s, 1&#39;r, 2&#39;r) trans-alcohol
    EP0529835B1 (en) Optical resolution of (+/-)-2-(4-isobutylphenyl) propionic acid
    JP2006169158A (en) Process for producing optically active amino acids
    EP0411074A1 (en) Resolution process
    EP0906900B1 (en) A process for preparing optically active 2-hydroxy-methyl-3-phenylpropionic acid
    RU2015953C1 (en) Process for splitting 2,2-dimethylcyclopropanecarboxylic acid racemate
    JP4005168B2 (en) Process for producing optically active 2-aryloxypropionic acid
    EP0441979B1 (en) Optically active 2-(alkyl-substituted phenyl)-propionic acid derivative and optical resolution of ( )-1-methyl-3-phenylpropylamine
    JP4812434B2 (en) Process for producing optically active (S) -2-methyl-6-oxoheptanoic acid
    EP1484315A1 (en) Process for production of optically active beta-phenylalanine
    GB2394473A (en) Racemization of optically active 2-substituted phenyl glycine esters
    KR20040035568A (en) Process for Racemate Resolution of 3-Aminopentanenitrile
    WO2001017944A1 (en) Process for producing optically active aminoalcohol
    JP4218310B2 (en) Process for producing optically active 2-amino-2-phenylethanol and its intermediate
    JP3694923B2 (en) Process for producing optically active 1- (2,4-dichlorophenyl) ethylamine
    JPH06116214A (en) Optically active amine compound, production method thereof, intermediate thereof and use thereof
    JPH085840B2 (en) Optical resolution method of jasmonic acid
    CN1910180A (en) Process for the preparation of 2-(ethoxymethyl)-tropane derivatives
    EP0298695A2 (en) Tartaric acid amide derivative and method of producing the same

    Legal Events

    Date Code Title Description
    PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

    Free format text: ORIGINAL CODE: 0009012

    17P Request for examination filed

    Effective date: 20040910

    AK Designated contracting states

    Kind code of ref document: A1

    Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT SE SI SK TR

    AX Request for extension of the european patent

    Extension state: AL LT LV MK RO

    RIC1 Information provided on ipc code assigned before grant

    Ipc: 7C 07M 7/00 B

    Ipc: 7C 07B 57/00 B

    Ipc: 7C 07C 229/34 B

    Ipc: 7C 07C 227/20 B

    Ipc: 7C 07C 233/47 B

    Ipc: 7C 07C 231/20 A

    A4 Supplementary search report drawn up and despatched

    Effective date: 20050301

    17Q First examination report despatched

    Effective date: 20071221

    GRAP Despatch of communication of intention to grant a patent

    Free format text: ORIGINAL CODE: EPIDOSNIGR1

    RIC1 Information provided on ipc code assigned before grant

    Ipc: C07B 57/00 20060101ALI20080627BHEP

    Ipc: C07C 229/34 20060101ALI20080627BHEP

    Ipc: C07C 227/20 20060101ALI20080627BHEP

    Ipc: C07C 233/47 20060101ALI20080627BHEP

    Ipc: C07C 231/20 20060101AFI20080627BHEP

    STAA Information on the status of an ep patent application or granted ep patent

    Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

    18D Application deemed to be withdrawn

    Effective date: 20081106